BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2492 related articles for article (PubMed ID: 14566475)

  • 1. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer.
    Beckmann GK; Hoppe F; Pfreundner L; Flentje MP
    Head Neck; 2005 Jan; 27(1):36-43. PubMed ID: 15459918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined radiotherapy with cis- or carboplatin in advanced head and neck tumors].
    Zamboglou N; Pape H; Schnabel T; Wurm R; Bannach B; Fürst G; Schmitt G
    Strahlenther Onkol; 1989 Sep; 165(9):647-51. PubMed ID: 2678546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors].
    Fietkau R; Iro H; Grabenbauer GG; Altendorf-Hofmann A; Sauer R
    Strahlenther Onkol; 1991 Dec; 167(12):693-700. PubMed ID: 1763405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Weekly paclitaxel with concurrent intensity-modulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial].
    Chen CY; Lu TX; Zhao C; Lu LX; Han F; Sun Y
    Ai Zheng; 2007 Apr; 26(4):398-402. PubMed ID: 17430660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
    Herchenhorn D; Dias FL; Viegas CM; Federico MH; Araújo CM; Small I; Bezerra M; Fontão K; Knust RE; Ferreira CG; Martins RG
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):696-702. PubMed ID: 20421154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
    Amrein PC; Clark JR; Supko JG; Fabian RL; Wang CC; Colevas AD; Posner MR; Deschler DG; Rocco JW; Finkelstein DM; McIntyre JF
    Cancer; 2005 Oct; 104(7):1418-27. PubMed ID: 16116597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
    Finnegan V; Parsons JT; Greene BD; Sharma V
    Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
    Papadimitrakopoulou VA; Dimery IW; Lee JJ; Perez C; Hong WK; Lippman SM
    Cancer J Sci Am; 1997; 3(2):92-9. PubMed ID: 9099459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Forastiere A; Arquette M; Costa F; Heelan R; Huang Y; Kelsen DP
    Cancer J; 2000; 6(5):316-23. PubMed ID: 11079171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial.
    Cmelak AJ; Murphy BA; Burkey B; Douglas S; Shyr Y; Netterville J
    Head Neck; 2007 Apr; 29(4):315-24. PubMed ID: 17252600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
    Moreno-Jiménez M; Valero J; López-Picazo JM; Arbea L; Aristu J; Cambeiro M; Alcalde J; Martínez-Monge R
    Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: a phase I study.
    Comella G; Frasci G; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Ruffolo P; Comella P
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-113-S12-116. PubMed ID: 9331134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 125.